Clinical Trials
25
Active:0
Completed:14
Trial Phases
4 Phases
Phase 1:2
Phase 2:9
Phase 3:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Not Applicable
13 (52.0%)Phase 2
9 (36.0%)Phase 1
2 (8.0%)Phase 3
1 (4.0%)Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx
Phase 2
Completed
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2005-10-21
- Last Posted Date
- 2013-03-26
- Lead Sponsor
- Aichi Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT00243113
- Locations
- 🇯🇵
Aichi Cancer Center, Nagoya, Aichi, Japan
🇯🇵Hirosaki University, School of Medicine, Hirosaki, Aomori, Japan
🇯🇵Chiba University, Chiba City, Chiba, Japan
Fluorouracil, Cisplatin, and Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Nasopharyngeal Cancer
Phase 2
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-05-15
- Lead Sponsor
- Aichi Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT00093665
- Locations
- 🇯🇵
National Hospital Organization - Medical Center of Kure, Hiroshima, Japan
🇯🇵Kanazawa University, Kanazawa, Japan
🇯🇵Kyoto Prefectural University of Medicine, Kyoto, Japan
News
Olomorasib Plus Pembrolizumab Shows Promise in KRAS G12C-Mutated NSCLC
Olomorasib combined with pembrolizumab demonstrated a 77% overall response rate in first-line NSCLC patients with KRAS G12C mutations, regardless of PD-L1 expression.